TScan Therapeutics, Inc. - Common Stock (TCRX)

Frequently Asked Questions About TScan Therapeutics, Inc. - Common Stock (TCRX)

How can investors find more information about TScan Therapeutics?

Investors can find more information about TScan Therapeutics by visiting the company's official website, where they can access press releases, financial reports, and details about its clinical trials and projects. Additionally, they can review filings on the Securities and Exchange Commission (SEC) website for comprehensive financial disclosures.

How does TScan ensure safety in its therapies?

TScan Therapeutics ensures the safety of its therapies through rigorous preclinical and clinical testing. The company adheres to strict regulatory guidelines and protocols to evaluate the safety and efficacy of its TCR-based therapies before they are administered to patients, thereby prioritizing patient well-being at all stages of development.

How does TScan Therapeutics engage with clinical trials?

TScan Therapeutics actively engages in clinical trials as part of its development pipeline. The company is focused on advancing its lead candidate therapies through various phases of clinical research, designed to evaluate their safety, efficacy, and overall benefit for patients suffering from cancer and infectious diseases.

Is TScan Therapeutics a public company?

Yes, TScan Therapeutics is a public company and its common stock is traded on the Nasdaq under the ticker symbol TCRX. The company went public through an initial public offering (IPO), which has provided it with capital to support its research and development efforts.

What are the main challenges TScan Therapeutics faces?

Like many companies in the biotechnology sector, TScan Therapeutics faces challenges such as regulatory hurdles, competition in the rapidly evolving field of immunotherapy, and the need for consistent funding to support extensive research and development efforts. The company is focused on overcoming these challenges through strategic planning and partnerships.

What does TScan Therapeutics, Inc. do?

TScan Therapeutics, Inc. is a biotechnology company focused on the discovery and development of novel T cell receptor (TCR)-based therapies. These therapies are designed to treat various cancers and infectious diseases by harnessing the body's immune system. Through innovative technology, TScan is identifying and targeting antigens that are critical in driving the immune response.

What funding has TScan Therapeutics secured?

TScan Therapeutics has secured substantial funding through multiple rounds of private investment as well as its IPO. The funds raised support the development of its therapeutic programs, expansion of clinical trials, and operational growth, ensuring that the company can prioritize its innovative research initiatives.

What future developments can we expect from TScan?

In the future, TScan Therapeutics plans to advance its lead therapeutic candidates through clinical trials and expand its pipeline of TCR therapies for various cancers and infectious diseases. The company aims to leverage its innovative platform for continued discoveries, ultimately enhancing its impact in the field of immunotherapy.

What is TScan's approach to personalized medicine?

TScan Therapeutics adopts a personalized medicine approach by developing TCR-based therapies tailored to individual patients' tumor profiles. By identifying specific antigens present in a patient's cancer, TScan aims to create targeted therapies that maximize the immune response while minimizing adverse effects, enhancing treatment outcomes.

What is TScan's primary therapeutic focus?

TScan Therapeutics primarily focuses on developing T cell receptor-based therapies to combat cancer. By specifically targeting tumor-associated antigens, the company aims to create highly effective treatments that can improve patient outcomes in various cancer types.

What is TScan's technology platform?

TScan Therapeutics utilizes a unique technology platform that integrates T cell receptor screening, antigen discovery, and affinity maturation processes. This platform allows the company to identify and validate specific TCRs that can efficiently recognize and target cancer cells, thereby facilitating the development of effective immunotherapies.

What is TScan's vision for the future?

TScan Therapeutics envisions a future where T cell therapies become the standard of care for patients with cancer and infectious diseases. Its mission is to leverage its innovative technology platform to discover and develop effective therapies that can significantly improve patient outcomes and quality of life.

What milestones has TScan achieved?

TScan Therapeutics has achieved several key milestones, including the initiation of clinical trials for its leading TCR therapeutic candidates, successful completion of preclinical studies, and collaborations with leading research institutions. These milestones demonstrate the company's commitment to advancing innovative therapies for patients.

What sets TScan apart from other biotech companies?

TScan Therapeutics stands out from other biotech companies through its innovative focus on T cell receptor therapy and its unique technology platform that enables the rapid identification of tumor-specific antigens. This distinct approach may lead to more precise and effective treatment options for cancer, offering a competitive edge in the immunotherapy landscape.

What types of cancers are TScan's therapies targeting?

TScan's therapies are targeting a range of cancers, including but not limited to solid tumors such as melanoma, ovarian cancer, and lung cancer, as well as hematological malignancies like leukemia. The company's goal is to develop personalized therapies that leverage the immune system to effectively respond to these diseases.

When was TScan Therapeutics founded?

TScan Therapeutics was founded in 2016 by a team of experienced scientists and business leaders. The company emerged from research conducted at Harvard Medical School and the Massachusetts Institute of Technology (MIT), which laid the groundwork for its novel approach to T cell therapy.

Where is TScan Therapeutics headquartered?

TScan Therapeutics is headquartered in Cambridge, Massachusetts. This location places the company among a vibrant community of biotechnology firms, research institutions, and academic organizations, facilitating collaboration and innovation in the field of immunotherapy.

Who are TScan Therapeutics' collaborators?

TScan Therapeutics collaborates with a variety of academic institutions, pharmaceutical companies, and research organizations. These collaborations aim to enhance the development of TCR-based therapies and improve the understanding of T cell biology in the context of cancer and infectious diseases.

Who is TScan Therapeutics' leadership team?

TScan Therapeutics' leadership team is composed of experienced professionals from various fields, including biotechnology, pharmacology, and business. The team includes co-founders and executives with a proven track record in drug development and commercialization, fostering a culture of innovation and strategic vision.

What is the current price of TScan Therapeutics, Inc. - Common Stock?

The current price of TScan Therapeutics, Inc. - Common Stock is 1.270

When was TScan Therapeutics, Inc. - Common Stock last traded?

The last trade of TScan Therapeutics, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025